PDCD1 and neoplasm: In fact, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and its ligand PD-L1 inhibitors proved to interfere with T-cell inhibitory pathways, thereby overcoming tumor immune subversion [87].